Beta Finch - S&P 100 - EN

Beta Finch
  • 5.0 (1)
  • Investing
  • Updated Weekly

Top 100 US-listed companies by market capitalization. AI-powered earnings call analysis for S&P 100 (SP100). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

  1. 4d ago

    Oracle Q1 2027 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: AI_LEADERS (https://betafinch.com/groups/AI_LEADERS) ────────── WELCOME TO BETA FINCH, your AI-powered earnings breakdown of the companies moving markets. I'm Alex. JORDAN: And I'm Jordan. Today we're digging into Oracle's fiscal Q1 2027 report, and Alex, this one's got some big numbers in it. ALEX: It really does — but before we get into it, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, now let's get into it because Oracle's CFO Hilary Maxson used the word "acceleration" to describe the quarter, and honestly, the numbers back that up. ALEX: Total revenue hit a record $19.3 billion, up 30% year-over-year. What's notable is that revenue actually grew sequentially from Q4 to Q1 — historically that hasn't happened for Oracle. A strong Q4 usually meant a softer Q1. JORDAN: Right, and the real engine here is cloud infrastructure — OCI revenue was $7.4 billion, up 121% year-over-year. That's after 93% growth last quarter, so this business is actually speeding up, not slowing down. ALEX: Cloud apps grew a more modest 10%, but within that, Fusion grew 14% and industry apps grew over 20%. Non-GAAP EPS came in at $1.92, up 30%. And then there's the RPO number — remaining performance obligations jumped $26 billion in just one quarter. JORDAN: That RPO detail is worth pausing on. Management said the vast majority of that new backlog came through prepayments or "bring your own hardware" arrangements — meaning it doesn't require Oracle to put up more of its own capital. They now expect about half of total RPO to convert into revenue over the next 36 months. ALEX: Which matters a lot for the CapEx conversation, because Oracle spent $28 billion in CapEx this quarter alone, leading to negative free cash flow of $5 billion. Full-year CapEx guidance stays at $90-95 billion. JORDAN: On the Q&A, one exchange stood out to me — an analyst pushed CFO Hilary Maxson on when free cash flow turns positive again. She wouldn't give a timeline but said each data center project, once ramped, converts to free cash flow at close to 100% of post-tax EBITDA, essentially calling the business "self-funding" over time. ALEX: There was also a good back-and-forth on gross margins, which declined this quarter as expected. Maxson was pretty clear that operating margin — which held flat around 42% — is the metric she wants investors focused on, not gross margin, since the infrastructure business is structurally lower-margin but requires much less R&D and sales spend. JORDAN: On the infrastructure side, Co-CEO Clay Magouyrk shared some eye-popping delivery stats — 850 megawatts of AI capacity and over 300,000 GPUs delivered since Q4, almost triple what they delivered in all of Q4. GPU utilization sits at 97.9%, and — this one surprised me — GPUs coming up for renewal are actually being renewed or resold at a 20% premium to their original contracts. ALEX: That's a strong signal on hardware longevity in a market that's been nervous about AI infrastructure depreciation. Magouyrk also addressed concerns about delays at the New Mexico and Wisconsin data centers directly, saying neither will impact fiscal 2027 revenue guidance, and stressed Oracle has a broad, diversified pipeline of sites so no single delay creates a major hit. JORDAN: On the apps side, Co-CEO Mike Sicilia leaned into the AI-agents story — customers used embedded AI capabilities more than 150 million times in the quarter, AI agents executed 3.5 million times in production, nearly doubling quarter-over-quarter, and there are now over 2,300 AI agents live with customers, up 90% sequentially. ALEX: They also announced NetSuite Next, a new AI-infused version of NetSuite, and noted their AI Connector Service link This episode includes AI-generated content.

  2. Sep 3

    Broadcom Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS) ────────── WELCOME TO BETA FINCH, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Broadcom's fiscal Q3 2026 numbers—and folks, these are some genuinely wild numbers. ALEX: Before we get into it, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And it's a good quarter to have that disclaimer front and center, because Hock Tan basically stood up and said "we're just getting started," and then backed it up with a $230 billion revenue forecast for 2028. ALEX: Let's start with the headline numbers. Q3 revenue came in at $29.6 billion, up 86% year-on-year. Operating income hit $20.1 billion, up 92%, with a record 68% operating margin. And free cash flow? $13.7 billion, 46% of revenue. JORDAN: Those margins are the story for me. Gross margin actually dipped slightly, down to about 75%, because AI chips carry more memory content and lower margins than the rest of the business. But operating margin still climbed because revenue is growing so much faster than expenses. That's operating leverage doing exactly what it's supposed to do. ALEX: Right, and the AI piece specifically—AI semiconductor revenue was $16.7 billion for the quarter, more than tripling year-over-year. That's now 56% of total revenue, up from 49% just last quarter. JORDAN: This company has essentially transformed into an AI infrastructure company that happens to also sell broadband chips and VMware software. ALEX: Speaking of which, let's talk customers, because this is where it gets interesting. Broadcom has six custom AI chip customers, but Hock Tan really zeroed in on four: Google, Anthropic, OpenAI, and Meta. JORDAN: The Google relationship is the elder statesman here—a decade of TPU development, and they just signed a long-term deal for "multi-tens of billions of dollars" of TPUs annually. They shipped the new Ironwood TPU v7 this quarter and are already ramping the next-gen v8i. ALEX: But the real headline is Anthropic. Tan said Anthropic is on track to become Broadcom's largest XPU customer in 2027, deploying 5 gigawatts of TPU v8i next year and then 10 more gigawatts in 2028. JORDAN: And OpenAI isn't far behind—their custom chip, nicknamed Jalapeño, is already reportedly outperforming Nvidia's Grace Blackwell in inference workloads at, according to Tan, less than half the cost. OpenAI's on pace for over 5 gigawatts by 2028, making them Broadcom's second-largest customer. ALEX: That "half the cost" line is the thesis of the whole call, honestly. Custom silicon, co-designed for a specific model's workload, beats a general-purpose GPU on performance and cost. That's Broadcom's pitch to the market. JORDAN: Now let's talk about the number that got everyone's attention: guidance. Q4 AI revenue guided to $21.7 billion, up 236% year-on-year. Full fiscal 2026 AI revenue now expected at $58 billion. ALEX: And then they went further than usual—giving multi-year guidance. AI revenue is expected to double to $115 billion in fiscal 2027, then double again to $230 billion in fiscal 2028. JORDAN: That's an unusually bold move for a company to lock in two years out. And CFO Amie Thuener was clear they don't plan to update it quarterly—so this is a stake in the ground, not a rolling estimate. ALEX: On the Q&A, analysts pushed hard on whether that's really achievable. Stacy Rasgon from Bernstein did some math on gigawatts versus dollars, and Tan clarified something important: not all the gigawatt capacity they've outlined will necessarily be "deployed" in that window—some of it depends on data centers, power, and shells being physically r This episode includes AI-generated content.

  3. Sep 2

    Palo Alto Networks Q4 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com ────────── WELCOME TO BETA FINCH — PANW Q4 FY2026 ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're digging into Palo Alto Networks' fiscal Q4 2026 results. This one's a big report to close out their fiscal year. JORDAN: Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Right, so let's get into it, because Palo Alto had a genuinely record quarter. RPO — that's remaining performance obligations, basically the backlog of contracted future revenue — crossed $20 billion for the first time, landing at $21.2 billion, up 34%. JORDAN: And the number that really jumped out to me was Next-Generation Security ARR, or NGS ARR, hitting $9.1 billion, up 63%. They added almost $1 billion in net new NGS ARR in a single quarter. CFO Dipak Golechha pointed out that's roughly what the entire company's NGS ARR was back in his first quarter as CFO in 2021. That's the kind of comparison that really puts scale into perspective. ALEX: Total revenue for the quarter was $3.41 billion, up 34%, and full-year revenue came in at $11.5 billion, up 24%. Non-GAAP EPS beat guidance at $1.02, and operating margin for the year expanded to 29.2%. JORDAN: What's notable is that margin expansion happened while they were digesting their two biggest acquisitions ever — CyberArk, now rebranded Idira, and Chronosphere. Usually big M&A drags on margins for a while, but management said CyberArk's cost synergies are three to six months ahead of schedule. ALEX: Let's talk strategy, because CEO Nikesh Arora spent a lot of time on what he called three AI "inflection points" over the last several months — the shift from prompting to autonomous agents, the "Mythos moment" where AI models got scary good at finding vulnerabilities, and now a move toward open-weight, sovereign AI models. His overall thesis: all three point toward the same conclusion. JORDAN: Which is platformization — get customers to consolidate onto one unified security architecture instead of stitching together point products. They hit about 220 net new "platformizations" in the quarter, more than double the pace from two years ago, and platformized customers are showing net revenue retention above 120%. ALEX: They also called out some serious deal sizes — a $126 million deal with a global telecom, $72 million with an IT services firm, $53 million with a payments company. And Prisma AIRS, their AI security product, crossed $100 million in ARR in just four quarters — fastest product scale in company history. JORDAN: XSIAM, their security operations platform, is also cruising — over $700 million in ARR, up 70%, past 1,000 customers. And on the observability side, since closing Chronosphere, that ARR has more than doubled past $500 million. Combined, XSIAM and observability are now a billion-dollar-plus business that basically didn't exist a few years ago. ALEX: There was also a bit of breaking news on the call — they closed an acquisition of a company called Console the same day, focused on AI-driven IT and security operations, folding into their Cortex team. JORDAN: On the Q&A side, I thought the most candid moment was Nikesh basically saying M&A isn't a strategy for them — it's a consequence of watching 40 or 50 funded startups and jumping in when one of them nails a technology shift before Palo Alto's internal roadmap gets there. Refreshingly blunt for a CEO. ALEX: There was also a fun exchange about the CyberArk integration — a new "Modern PAM" product just went GA, and Nikesh made the case that identity security for AI agents and machine identities is a wide-open category with no established leader yet, which is where he thinks Idira has a real head start. JORDAN: This episode includes AI-generated content.

  4. Sep 1

    Medtronic Q1 2027 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) ────────── WELCOME TO BETA FINCH — MEDTRONIC Q1 FY2027 ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Medtronic's fiscal 2027 first quarter — and it's a big one. JORDAN: Yeah, a lot to unpack here. Big beats, a couple of surprise M&A announcements, and a robotics story that's getting more interesting by the day. ALEX: Before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: With that out of the way, let's get into the numbers, because they were strong. ALEX: $9.8 billion in revenue, up 13.7% organically, adjusted EPS of $1.45 — both well ahead of what analysts were expecting. Now, a chunk of that growth came from an accounting quirk: fiscal 2027 is a 53-week year, and that extra week added about 670 basis points to growth this quarter. JORDAN: Right, but even stripping that out, CFO Thierry Piéton said it was their strongest quarterly performance in nearly eight years, excluding COVID comparisons. So this wasn't just a calendar trick — the underlying business is actually accelerating. ALEX: And it was broad-based. CEO Geoff Martha kept hammering that point — it's not one hot product carrying the quarter, it's basically every major business line pulling its weight. JORDAN: The headline story, though, is Cardiac Ablation Solutions — CAS. That business grew 88% worldwide, 139% in the U.S. They crossed $2 billion in trailing twelve-month revenue, ahead of schedule. Their Sphere-9 catheter picked up nine points of U.S. market share this quarter alone. ALEX: Nine points in one quarter is wild for medtech. JORDAN: It really is. And they're guiding CAS to grow at 2.5 times the broader electrophysiology market for the full year — even upgraded that to more than 3x for Q2. The U.S. installed base for their Affera system grew 35% sequentially, on top of 40% the quarter before. ALEX: Which tells you they're nowhere near saturated. Management said 75% of that installed base is still concentrated in high-volume hospital centers, so there's a long runway into smaller accounts. JORDAN: Beyond CAS, Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies grew 13%, and Surgical — their biggest unit at over $6 billion a year — grew 9%. Pelvic health jumped 15%, largely thanks to Altaviva, where procedures doubled sequentially. ALEX: Now let's talk strategy, because Medtronic made two acquisition-adjacent announcements the same morning as earnings. First, a $700 million strategic investment and distribution deal with Cornerstone Robotics for their Sentire surgical robot, outside the U.S. JORDAN: This one got some pointed questions on the call. One analyst basically asked, "Does this mean you've lost confidence in Hugo, your own robot?" And Martha pushed back hard — said it's the opposite. Hugo's on track to hit 50,000 procedures by year-end, growing at twice the market rate. Cornerstone is about extending reach into international markets where Hugo isn't the right fit, not replacing it. ALEX: Basically building a multi-platform robotics portfolio instead of betting everything on one system. JORDAN: Exactly — and Thierry noted the financial impact this year is minimal, mostly just some foregone interest on that investment, but they expect real revenue and margin lift starting in fiscal 2028. ALEX: The second deal was Pi-Cardia, in structural heart — first FDA-cleared technology for leaflet modification in TAVR procedures for patients at risk of coronary obstruction. That's part of a broader doubling-down in structural heart, alongside their earlier investment in Anteris. JORDAN: On guidance, they ra This episode includes AI-generated content.

  5. Aug 29

    Zoetis Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex. JORDAN: And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride. ALEX: It really is. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good to have that out front. So let's set the scene. Zoetis reported second quarter revenue of $2.5 billion — flat on a reported basis, actually down 1% organically. Adjusted net income came in at $781 million, down 2% organically. And here's the headline: they cut full-year guidance. ALEX: Yeah, this wasn't a small tweak either. New revenue guidance is $9.12 to $9.32 billion, which works out to a decline of 3% to 1% for the year. Adjusted net income guidance dropped to a range implying a decline of 9% to 5%. That's a meaningful reset. JORDAN: So what happened? Basically, the U.S. Companion Animal business — think dogs and cats, not cattle and chickens — got hit hard. Revenue there was down 11% in the U.S. Fewer vet visits, pet owners being more price-conscious, and a lot more competitors piling into categories Zoetis basically invented, like dermatology treatments. ALEX: Right, and that's the key tension here. Their blockbuster drug Apoquel and the whole Key Dermatology franchise — U.S. dermatology revenue was down 18% in the quarter. New competitors are using aggressive discounting and rebates to steal share, and it's not growing the overall market, it's just splitting up a shrinking pie. JORDAN: Even so, Zoetis still holds about 86% in-clinic share in U.S. dermatology, even after losing 10 points year-over-year. So they're still dominant, just under real pressure for the first time in a while. ALEX: And parasiticides — flea, tick, heartworm meds like Simparica — were basically flat globally, with the U.S. side down 6%. Management said it's less about a specific competitor and more about a broader pullback in vet visits. JORDAN: But here's the plot twist — it's not all bad news. Livestock had a phenomenal quarter, up 11% globally, and 23% in the U.S., partly boosted by demand for cattle parasiticides tied to that New World screwworm outbreak. And Diagnostics grew 12%, driven by point-of-care testing demand. ALEX: So basically, the pet side is struggling, but the farm animal side and the diagnostics side are picking up a lot of the slack. JORDAN: Exactly — that diversification is doing real work for them right now. ALEX: Let's talk strategy, because CEO Kristin Peck was pretty clear about their playbook. Instead of cutting list prices — which she called a "permanent structural change" — they're doing what's called gross-to-net investment. Basically targeted rebates, promotions, and bundling deals to protect market share without blowing up their pricing structure long-term. JORDAN: It's a defend-the-fort strategy. Protect volume and share now, keep the sticker price intact, and hope the competitive intensity eases once the market sorts itself out. CFO Wetteny Joseph said full-year price realization could land anywhere from flat to down 2%, depending on how aggressive they need to get. ALEX: There's also a leadership shakeup worth mentioning. Wetteny Joseph, the CFO, is stepping down after five years — a new hire, Jay Saccaro, is coming in not just as CFO but in a newly created combined CFO and Chief Operating Officer role, overseeing manufacturing and supply chain too. That's a pretty significant restructuring of the C-suite, aimed at s This episode includes AI-generated content.

  6. Aug 29

    Walmart Q2 2027 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL) ────────── **BETA FINCH: Walmart Q2 FY2027 Earnings Breakdown** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex. JORDAN: And I'm Jordan. Today we're digging into Walmart's fiscal second quarter 2027 results. ALEX: Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good ground rules. So, Alex, Walmart just posted a really strong quarter. Where do we start? ALEX: Let's start with the headline numbers. Enterprise sales grew 5% in constant currency — that's the top end of their guidance. Adjusted operating income was up over 17%, and EPS grew more than 19%. Walmart U.S. comps came in at 2.6%, Sam's Club U.S. hit 4.4%, and International was up nearly 8%, led by China and India. JORDAN: But here's the twist — a good chunk of that operating income growth wasn't "organic," so to speak. Walmart received about $2.9 billion in tariff refunds this quarter, and that added roughly 750 basis points to operating income growth. Strip that out, and underlying profit growth was still solid — at the top end of their 7-10% guidance — but the headline number is inflated by a one-time item. ALEX: Right, and CFO John David Rainey was upfront about this. He basically said, "look at Q2 and Q3 together" to get the real picture, because they're plowing a lot of that refund money right back into price cuts rather than just letting it flow to the bottom line. JORDAN: Which explains the rollback numbers — Walmart U.S. had over 11,000 rollbacks by the end of the quarter, up from 7,200 at the end of Q1. That's a huge jump, and CEO John Furner called it one of the highest counts he can remember. ALEX: It's a pretty deliberate strategy — take a windfall from tariff refunds, funnel it into lower prices on things like ground beef and pantry staples, and try to lock in market share. Furner mentioned food share gains were some of the strongest they've seen in a while. JORDAN: And that's the bet, right? Price investments now, in hopes it builds durable trust and share gains that outlast the promotional period. Management was pretty candid that there's a lag — you see unit growth first, and the real payoff comes over months, not days. ALEX: Let's talk about the stuff that weighed on results, too. Health and wellness was a real drag this quarter — that's their pharmacy business. New regulation called "Maximum Fair Price" for certain drugs hit comp sales by about 125 basis points, worse than they'd expected. They also lost the GLP-1 drug tailwind that helped in prior years. JORDAN: Which is interesting because if you back out health and wellness, their core categories — grocery, general merchandise — have been remarkably steady, in that 3-4% range for two and a half years. So the topline wobble is really a pharmacy story, not a "Walmart is losing its core mojo" story. ALEX: Now, the part I find genuinely exciting is the platform story — eCommerce, advertising, membership, Marketplace. Global eCommerce grew 23%. Advertising was up 38% globally. Marketplace in the U.S. grew 52%. And membership fee income hit an all-time high, up 17%. JORDAN: This is the piece investors should really pay attention to. Rainey made a striking comparison — Walmart's U.S. comp was only about 2.5%, but operating income grew 10% excluding tariff effects. That's four times the revenue growth rate, and he said they haven't seen that kind of profit leverage relative to comp sales in two decades. ALEX: Because these newer businesses — advertising, Marketplace, membership — carry much higher margins, and they're growing faster than the core retail business. Roughly half of profit growth this quarter came from those areas. JORDAN: The This episode includes AI-generated content.

  7. Aug 29

    Vertex Pharmaceuticals Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' second quarter 2026 results — and there's a lot going on: strong numbers, a major acquisition, and pipeline news across four disease areas. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Alright, Alex, let's start with the headline numbers because they're pretty solid. ALEX: Yeah, Vertex posted $3.3 billion in total revenue for Q2, up 12% year-over-year. That's driven largely by the cystic fibrosis franchise, which grew 11%, but also some real acceleration from the newer products. JORDAN: Right, and this is the part I find genuinely interesting — CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, brought in $76 million this quarter. That's roughly 75% sequential growth and over 150% year-over-year. They had more infusions in the first half of 2026 than in all of 2025 combined. ALEX: That's a huge inflection point. And it's not slowing down either — they had over 100 patient initiations for a third straight quarter, plus a pediatric approval for ages two to eleven that came through in just 53 days post-filing. JORDAN: Then there's JOURNAVX, their non-opioid pain drug, at $50 million in revenue — about 70% sequential growth. The prescription numbers are climbing fast too, roughly 535,000 scripts this quarter. But here's the nuance: gross-to-net is still messy because of a patient support program covering people whose insurance has restrictions like quantity limits. ALEX: Management said that normalizes more toward branded-drug norms in the first half of 2027, so investors watching margins on JOURNAVX should expect some lumpiness for a few more quarters. JORDAN: On profitability — non-GAAP EPS came in at $4.73, up 5% year-over-year. Gross margin was 85.6%, a slight step down from Q1, which they attributed to product mix as CASGEVY, which costs more to manufacture, becomes a bigger slice of revenue. ALEX: And they raised full-year revenue guidance to $13.1 to $13.2 billion, reiterating that $500 million-plus target for non-CF revenue this year. JORDAN: Now let's talk about the big strategic move — the Crinetics Pharmaceuticals acquisition. This is roughly an $8.8 billion deal, expected to close in Q3. ALEX: This is Vertex adding a fifth commercial pillar — rare endocrine diseases like acromegaly, CAH, and Cushing's syndrome. The two lead assets from Crinetics, paltusotine and atumelnant, are pegged at a combined peak sales opportunity of about $5 billion. JORDAN: It's being funded through cash on hand plus a $4.5 billion term loan, and management said it should become accretive to operating income in 2029 — so this is a multi-year bet, not an immediate earnings boost. ALEX: Let's talk pipeline, because there's a lot moving. The renal franchise is arguably the most important near-term catalyst — povetacicept, or "Povi," for IgA nephropathy has an FDA decision date of November 30th after a really strong phase III interim analysis. JORDAN: And on the call, Reshma Kewalramani, the CEO, made a pretty confident case for Povi's differentiation — she cited a 52% reduction in proteinuria, which she called numerically the best in class, plus once-monthly dosing via a small-volume auto-injector patients can use at home. ALEX: There was also a great analyst question about how Vertex sees eGFR data compare against a competitor's recently published numbers. Reshma's answer was essentially: strong proteinuria reduction should translate to GFR stabilization, and Vertex believes Povi's numbers on proteinuria, hematuria, and other biomarkers This episode includes AI-generated content.

  8. Aug 29

    Uber Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com ────────── BETA FINCH — Uber Technologies (UBER) Q2 2026 Earnings Breakdown ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex. JORDAN: And I'm Jordan. Today we're digging into Uber's second quarter 2026 results — and Alex, this was a loaded call. Delivery Hero, autonomous vehicles, a Waymo update — there's a lot here. ALEX: There really is. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, let's get into the numbers. ALEX: So gross bookings came in at more than $58 billion, up 22% year-over-year — that's above the high end of guidance, and it's the fourth straight quarter above 20% growth. Non-GAAP EPS was up 35%, and trailing 12-month free cash flow crossed $10 billion for the first time ever. JORDAN: That free cash flow number is the headline for me. Ten billion trailing twelve months — that's real operating leverage, not just top-line growth. And it's giving them room to do something pretty aggressive: the agreement to acquire Delivery Hero. ALEX: Right, and that deal basically doubles the number of markets where Uber can run both mobility and delivery side by side — pushing them toward nearly 100 markets. CFO Balaji Krishnamurthy laid out the integration timeline: assuming a close in the second half of 2027, they'd spend 2028 planning, then execute the core platform migration in 2029. JORDAN: That's a long runway. And notably, they actually pivoted about $4 billion of capital toward that deal in Q2 — buying Delivery Hero stock on the open market to be ready to move fast. That's part of why buybacks slowed to $3.5 billion so far this year instead of hitting their usual 50%-of-free-cash-flow pace. Balaji said they're "steadily" rebuilding repurchases — and when pushed on timing, he said months, not quarters. ALEX: Let's talk autonomous vehicles, because Dara Khosrowshahi spent a lot of time here. Uber's live in seven cities with AV partners right now, on track for 15 by year-end — Zoox in Vegas, Wayve in London and Tokyo, a Nuro-Lucid launch in the Bay Area, Baidu, Pony, more. JORDAN: What stood out to me is how he framed the whole AV landscape — comparing it to the foundation model race. Instead of one company winning everything, you get multiple players — Waymo, Zoox, Wayve, Nuro, Rivian, NVIDIA — and Uber's positioning itself as the commercialization layer underneath all of them, not betting on a single winner. ALEX: Which matters given the Waymo headlines lately. Dara addressed it directly — said Waymo remains an important partner, they'll keep operating in Austin and Atlanta into next year, but Uber's deliberately diversifying so they're not dependent on one AV provider. JORDAN: And the scale context he gave was useful — AVs are doing hundreds of thousands of trips per week against Uber's total of 300 million weekly trips. That's under half a percent of volume. So this is very much still an early-innings story, even with all the partnership headlines. ALEX: There was also a really interesting tidbit on the economics — Dara said Uber's built-in demand drives utilization of mid-to-high-20s, even low-30s trips per vehicle per day for AV partners. That's a meaningful data point on how Uber's platform accelerates the monetization case for these robotaxi partners. JORDAN: On the U.S. mobility side, Balaji broke down what's driving the acceleration everyone's been watching for — insurance cost savings being reinvested into markets like California, product innovation on both ends of the spectrum — Uber Reserve and Black on the premium side, Wait & Save on the value side — and then sparse markets, where less than 10% of eligible U.S. consumers have used Uber in the past year, versus over This episode includes AI-generated content.

See All (281)

About

Top 100 US-listed companies by market capitalization. AI-powered earnings call analysis for S&P 100 (SP100). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

Information